Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M, Hanley WD, Petry AS, Friedman EJ, Kost JT, Breidinger SA, Lasseter KC, Robson R, Lunde NM, Wenning LA, Stone JA, Wagner JA. Iwamoto M, et al. Among authors: lasseter kc. Antimicrob Agents Chemother. 2009 May;53(5):1747-52. doi: 10.1128/AAC.01194-08. Epub 2009 Feb 17. Antimicrob Agents Chemother. 2009. PMID: 19223645 Free PMC article. Clinical Trial.
Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. Wenning LA, et al. Among authors: lasseter kc. Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8. doi: 10.1128/AAC.00005-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625763 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. Among authors: lasseter kc. Clin Pharmacol Ther. 2008 Feb;83(2):293-9. doi: 10.1038/sj.clpt.6100281. Epub 2007 Aug 22. Clin Pharmacol Ther. 2008. PMID: 17713476 Clinical Trial.
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC. Stone JA, et al. Among authors: lasseter kc. Antimicrob Agents Chemother. 2004 Mar;48(3):815-23. doi: 10.1128/AAC.48.3.815-823.2004. Antimicrob Agents Chemother. 2004. PMID: 14982770 Free PMC article. Clinical Trial.
Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Stone JA, et al. Among authors: lasseter kc. Antimicrob Agents Chemother. 2004 Nov;48(11):4306-14. doi: 10.1128/AAC.48.11.4306-4314.2004. Antimicrob Agents Chemother. 2004. PMID: 15504857 Free PMC article. Clinical Trial.
153 results